Approval · Notice of Compliance 31033 · 2023
APO-SUMATRIPTAN: Notice of Compliance 31033
Issued June 21, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31033
- Date
- June 21, 2023
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to the Package Insert. Update to Labels
- Canadian reference product
- IMITREX (Glaxo Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-SUMATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB